KRON Company Profile and Key Details

Q: Who are the executives of KRON?

Ms. Marni KottleChief Communications OfficerDr. Norbert W. Bischofberger Ph.D.Pres, Chief Executive Officer & DirectorDr. Christopher Dinsmore Ph.D.Chief Scientific OfficerMs. Allison Frisbee J.D.Senior Vice President & Deputy Gen. CounselDr. Elizabeth A. Olek D.O., M.P.H.Senior Vice President of Clinical Devel.Mr. Charles Lin Ph.D.Senior Vice President of TRN MappingMs. Sarah ConnorsVice President of Investor Relations & Corporation CommunicationsDr. Anders Vinther Ph.D.Senior Vice President of Pharmaceutical Devel. & ManufacturingDr. Yasir B. Al-Wakeel BCh, BM, MAChief Financial Officer & Head of Corporation Devel.Dr. Jorge F. DiMartino M.D., Ph.D.Chief Medical Officer & Executive Vice President of Clinical Devel.Ms. Barbara A. Kosacz J.D.Chief Operating Officer, Sec. & Gen. Counsel

NASDAQ : KRON

Kronos Bio

$0.88

0.0129+1.49%

At Close 4:00 PM

Not Actively Trading

58.83

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Kronos Bio, Inc. (KRON) stock surged +1.49%, trading at $0.88 on NASDAQ, up from the previous close of $0.87. The stock opened at $0.88, fluctuating between $0.87 and $0.88 in the recent session.

Stock Snapshot

0.8671

Prev. Close

53.65M

Market Cap

0.8701

Day Low

-0.822429906542056

P/E Ratio

-1.07

EPS (TTM)

-1.36

Cash Flow per Share

0.88

Open

60.97M

Number of Shares

0.881

Day High

96.6%

Free Float in %

2.73

Book Value

53.69K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jul 10, 2025	0.88	0.88	0.88	0.88	0
Jul 08, 2025	0.88	0.88	0.88	0.88	0
Jun 25, 2025	0.88	0.88	0.88	0.88	0
Jun 24, 2025	0.88	0.88	0.88	0.88	0
Jun 23, 2025	0.88	0.88	0.88	0.88	0
Jun 20, 2025	0.88	0.88	0.87	0.88	54.09K
Jun 18, 2025	0.88	0.90	0.87	0.87	4.02M
Jun 17, 2025	0.88	0.90	0.88	0.89	1.19M
Jun 16, 2025	0.88	0.89	0.88	0.89	183.81K
Jun 13, 2025	0.88	0.90	0.88	0.89	347.77K
Jun 12, 2025	0.87	0.89	0.87	0.88	227.06K
Jun 11, 2025	0.88	0.89	0.87	0.87	596.38K
Jun 10, 2025	0.87	0.90	0.87	0.89	316.77K
Jun 09, 2025	0.86	0.89	0.86	0.87	715.3K
Jun 05, 2025	0.86	0.90	0.86	0.87	11.96M
Jun 04, 2025	0.67	0.68	0.66	0.67	206.7K
Jun 03, 2025	0.66	0.69	0.66	0.68	769.47K
Jun 02, 2025	0.67	0.67	0.66	0.67	589.88K
May 30, 2025	0.67	0.68	0.67	0.68	477.17K
May 29, 2025	0.67	0.69	0.66	0.67	1.29M

Contact Details

San Mateo, CA 94402

United States

https://kronosbio.com 650 781 5200

About Company

Kronos Bio, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to the identification and advancement of innovative therapies for cancer. Its therapeutic strategy centers on modulating dysregulated transcription factors and the intricate transcriptional regulatory networks that fuel oncogenic activity. The company's primary investigational drug, entospletinib (ENTO), is an orally administered, selective inhibitor of spleen tyrosine kinase (SYK), designed for patients with acute myeloid leukemia. A registrational Phase 3 clinical trial is slated to evaluate ENTO in combination with induction chemotherapy for acute myeloid leukemia patients who possess NPM1 mutations. Furthermore, Kronos Bio is progressing KB-0742, an orally bioavailable cyclin dependent kinase 9 (CDK9) inhibitor, which is currently undergoing Phase 1/2 clinical assessment for the treatment of MYC-amplified solid tumors. Established in 2017, the company maintains its headquarters in San Mateo, California.

Stock Peers

ARGX

-18.76-2.15%

argenx SE$853.82 REGN

24.29+3.29%

Regeneron Pharmaceuticals, Inc.$762.63 UTHR

-8.11-1.54%

United Therapeutics Corporation$517.71 VRTX

-4.6-0.95%

Vertex Pharmaceuticals Incorporated$477.10 MDGL

-25.79-5.23%

Madrigal Pharmaceuticals, Inc.$467.32 KRYS

-25.73-7.01%

Krystal Biotech, Inc.$341.12 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ONC

-6.07-1.88%

BeOne Medicines AG$316.01 PRAX

0.08+0.03%

Praxis Precision Medicines, Inc.$307.83 LGND

-8.75-2.95%

Ligand Pharmaceuticals Incorporated$287.54

Frequently Asked Questions

What is the current Kronos Bio, Inc. (KRON) stock price?

Kronos Bio, Inc. (NASDAQ: KRON) stock price is $0.88 in the last trading session. During the trading session, KRON stock reached the peak price of $0.88 while $0.87 was the lowest point it dropped to. The percentage change in KRON stock occurred in the recent session was 1.49% while the dollar amount for the price change in KRON stock was $0.01.

KRON's industry and sector of operation?

The NASDAQ listed KRON is part of Biotechnology industry that operates in the broader Healthcare sector. Kronos Bio, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of KRON?

Ms. Marni Kottle
Chief Communications Officer
Dr. Norbert W. Bischofberger Ph.D.
Pres, Chief Executive Officer & Director
Dr. Christopher Dinsmore Ph.D.
Chief Scientific Officer
Ms. Allison Frisbee J.D.
Senior Vice President & Deputy Gen. Counsel
Dr. Elizabeth A. Olek D.O., M.P.H.
Senior Vice President of Clinical Devel.
Mr. Charles Lin Ph.D.
Senior Vice President of TRN Mapping
Ms. Sarah Connors
Vice President of Investor Relations & Corporation Communications
Dr. Anders Vinther Ph.D.
Senior Vice President of Pharmaceutical Devel. & Manufacturing
Dr. Yasir B. Al-Wakeel BCh, BM, MA
Chief Financial Officer & Head of Corporation Devel.
Dr. Jorge F. DiMartino M.D., Ph.D.
Chief Medical Officer & Executive Vice President of Clinical Devel.
Ms. Barbara A. Kosacz J.D.
Chief Operating Officer, Sec. & Gen. Counsel

How KRON did perform over past 52-week?

KRON's closing price is 35.38% higher than its 52-week low of $0.65 where as its distance from 52-week high of $1.46 is -39.73%.

How many employees does KRON have?

Number of KRON employees currently stands at 8.

Link for KRON official website?

Official Website of KRON is: https://kronosbio.com

How do I contact KRON?

KRON could be contacted at phone 650 781 5200 and can also be accessed through its website. KRON operates from 1300 South El Camino Real, San Mateo, CA 94402, United States.

How many shares of KRON are traded daily?

KRON stock volume for the day was 53.69K shares. The average number of KRON shares traded daily for last 3 months was 855.96K.

What is the market cap of KRON currently?

The market value of KRON currently stands at $53.65M with its latest stock price at $0.88 and 60.97M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	8
Beta	1.64
Sales or Revenue	$6.29M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

Employees	8
Beta	1.64
Sales or Revenue	$6.29M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

KRON Company Profile and Key Details

Kronos Bio

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Dividend & Fair Value

Company Overview

Valuation Metrics

Key Takeaways

Price Forecast & Outlook